Steroid-free liver transplantation in children.
(2003) The Lancet — Vol. 362, n° 9401, p. 2068-2070 (2003)
Files
9701.pdf
Restricted Access - Adobe PDF
- 67.23 KB
Details
- Authors
- Abstract
- Although corticosteroids have been part of immunosuppressive regimens since the early days of transplantation, steroid avoidance could be beneficial. To test this hypothesis in paediatric liver transplantation, we compared liver-transplantation under steroid-free immunosuppression in 20 children, who received combined tacrolimus and basiliximab, with that under tacrolimus and steroids in 20 matched historical recipients as a historical control group. 12-month rejection-free survival was 75% in the tacrolimus-basiliximab group compared with 50% in the steroid group (p=0.05). Growth in the first year after transplantation was significantly better in the tacrolimus-basiliximab group than in the steroid group. Steroid avoidance was, therefore, not harmful to our patients, and combining tacrolimus with basiliximab as a steroid substitution seems a safe alternative to tacrolimus and steroid immunosuppression.
- Affiliations
Citations
Reding, R., Gras, J., Sokal, E., Otte, J.-B., & Davies, H. F. S. (2003). Steroid-free liver transplantation in children. The Lancet, 362(9401), 2068-2070. https://doi.org/10.1016/S0140-6736(03)15104-5 (Original work published 2003)